Ebola
Journal: International Journal of Science and Research (IJSR) (Vol.9, No. 2)Publication Date: 2020-02-05
Authors : Anshupa Patel Gupta;
Page : 1858-1860
Keywords : Ebola virus; Ebola virus disease (EVD); vaccine;
Abstract
Ebola virus disease or simply Ebola is lethal viral hemorrhagic fever caused by Ebola viruses. Many outbreaks have been seen from 1976 to recent 2016, killing around 50 % of persons affected. The Ebola virus includes six species of virus out of which Zaire ebolavirus has highest mortality rate. To get protection against this virus, the vaccine was invented by scientists at the Public Health Agency of Canada (PHAC). In 2014, Merck got the licence to develop this from Newlink (which was first licensed from PHAC). Now Merck Sharp and Dohme Corp has got approval in December 2019 for manufacturing it under the trade name ERVEBO®. ERVEBO is a live recombinant viral vaccine in the form of sterile suspension for intramuscular injection. It is to be administered in single 1 ml dose. Though it has few adverse effects it will certainly be a milestone fighting against Ebola disease.
Other Latest Articles
- Does Knowledge Influence Risk Status of Oral Cancer? A Study among Students at Selected Colleges in Nagaland
- Colleges of Education Mathematics Tutors' Problems and Challenges associated with the Teaching of Quadratics using Completing the Square Approach
- Likes and Dislikes of Respondents
- Eating Behaviour among Adolescents
- Research of Parasitopa of Module of Rutilus Aralensis Deltas of Amudarya
Last modified: 2021-06-27 15:43:04